Results of phase III clinical trial of novel biosimilar of pembrolizumab (RPH-075).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ilya Pokataev, Konstantin Penkov, Lyudmila Zhukova, Daniil Stroyakovsky, Rashida Orlova, Marina Sekacheva, Igor Samoylenko, Ali Mudunov, Aleksandr Sobolev, Mikhail Fedyanin, Rustem Safin, Anastasia Mochalova, Irina Rozhkova, Ruslan Zukov, Vadim Kozlov, Vasilii Ignatiev, Olga Filon, Anna Podolyakina, Victoria Razzhivina, Andrey Andrianov
Institutions: Russian Railways, Moscow Clinical Scientific Center, Moscow City Oncology Hospital №62, St Petersburg University, Sechenov University, Ministry of Health of the Russian Federation, Russian Cancer Research Center NN Blokhin, Republican Oncological Clinical Dispensary, Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal, Government of the Republic of Tatarstan, Krasnoyarsk State Medical University, R-Pharm (Russia)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410817279